Although chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), this treatment is frequently inaccessible to patients, and approximately half relapse in spite of receiving CAR-T. This leaves a major area of need for novel options in patients with relapsed or refractory DLBCL.